Please login to the form below

Biocon

This page shows the latest Biocon news and features for those working in and with pharma, biotech and healthcare.

Mylan, Biocon’s Herceptin biosimilar launched in US

Mylan and Biocon have launched their biosimilar Herceptin (trastuzumab) under the brand name Ogivri, after Roche tried and failed to get an injunction on sales of biosimilars in the US. . ... Mylan/Biocon’s Herceptin biosimilar is the second to

Latest news

Amgen CEO says Aimovig is “one of most successful launches”

of weakness from biosimilar competition after Mylan/Biocon launched their Fulphila rival in July.
Roche eyes September FDA verdict for triple NSCLC therapy

Amgen and Allergan’s Mvasi biosimilar was cleared by the FDA last September, while Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan also have biosimilars in late-stage development.
Novartis doubles down on biosimilars with Biocon alliance

The companies will develop multiple immunology and oncology biosimilars. Already a big player in the emerging biosimilars market, Novartis has struck a deal with India’s Biocon in a bid to ... globally”. The deal with Novartis' subsidiary Sandoz
Mylan gets first biosimilar Herceptin OK from FDA

The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin ... Mylan said in a statement Ogivri is the
First Herceptin biosimilar cleared in Europe

favour of approval for Biocon and Mylan’s version of the drug in September. ... Biocon and Mylan withdrew the filing for their biosimilar in the EU, after questions were raised about manufacturing quality compliance issues, but said recently these have

More from news
Approximately 10 fully matching, plus 24 partially matching documents found.

Latest Intelligence

Deal Watch May 2016

Similarly, Bristol-Myers Squibb has called time on its deal with Biocon for IN-105/Tregopil [oral insulin]. ... Given the cost of the clinical studies going forwards, Biocon will now be seeking a new partner.
Pharma deals during February 2013

Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... Mylan and Biocon will share development and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Senior Medical Writer, MedComms Agency: Salary TBC

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Account Director or Senior Account Director: Salary TBC

Vice President: Competitive Salary Offered

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager– Medical Communications: (Negotiable - depending on experience)

Consultant: competitive salary

Subscribe to our email news alerts

PMHub

Add my company

Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat: A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product: In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team: Enhanced expertise to deliver impactful internal training programmes for healthcare clients...